C+D (Chemist+Druggist)

C+D (Chemist+Druggist)

Chemist + Druggist is a weekly magazine aimed at community pharmacists across the United Kingdom. It has been in circulation since its first issue in 1859. This subscription-based publication is managed by CMPMedica, a part of United Business Media. The magazine's circulation is verified by the Audit Bureau of Circulations, reaching a total of 13,675 copies. In each issue, Chemist + Druggist provides up-to-date news on business and clinical matters affecting UK community pharmacies. It includes articles and training resources that support pharmacists in their ongoing professional development, as well as insightful commentary and detailed features on topics that matter to the community pharmacy sector.

National, Trade/B2B
English
Magazine

Outlet metrics

Domain Authority
53
Ranking

Global

#400954

United Kingdom

#20922

Health/Pharmacy

#21

Traffic sources
Monthly visitors

Articles

  • 1 day ago | chemistanddruggist.co.uk | Kate Bowie

    HomeICB cuts will cause ‘turmoil’ at a local level, CPE warnsWhile the incoming 10-year health plan may be “pretty radical”, the scrapping of NHS England (NHSE) may “delay progress at a local level”, CPE director Alastair Buxton has said. Patel: “Those who are well connected get rehired with bigger titles and more pay" (Cagkan Sayin/Shutterstock)

  • 2 days ago | chemistanddruggist.co.uk | Kate Bowie

    Home‘Curtain of secrecy’: CPE committee urged to disclose voting recordFormer Royal Pharmaceutical Society (RPS) president Hemant Patel has slammed the contract negotiator’s "secret cabal [who] hide their votes”. “There was a leak about this negotiation – Who was the leaker?”

  • 2 days ago | chemistanddruggist.co.uk | Kate Bowie

    HomeGPhC can’t achieve ‘anything useful’ alone, Rudkin admits The GPhC’s chief executive has said that the pharmacy regulator can’t achieve “very much” on its own and has laid out plans to “hand off [issues] to another organisation”. “The regulator – acting alone – can't achieve very much”

  • 3 days ago | chemistanddruggist.co.uk | Molly Bowcott

    HomeMounjaro vs Wegovy – latest trial reveals which is ‘superior’ A head-to-head clinical trial by Mounjaro manufacturer Eli Lily has claimed its tirzepatide-based jab is “superior” to Wegovy’s semaglutide-based formula. “Tirzepatide was superior to semaglutide with respect to weight reduction”

  • 3 days ago | chemistanddruggist.co.uk | Molly Bowcott

    HomeNPA demands ‘re-run’ of pharmacy economic review The NPA has called for the community pharmacy economic review to be “re-run” following the announcement of the funding deal for 2024/25 and 2025/26. The NPA has called for the economic review “to be re-run" following the funding deal

C+D (Chemist+Druggist) journalists

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

Traffic locations